17:51 EST Vertex Pharmaceuticals (VRTX)’ non-opioid painkiller approved by FDA, Bloomberg says
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Meta Platforms, CVS Health upgraded: Wall Street’s top analyst calls
- Wells downgrades Vertex to Equal Weight on lack of catalysts
- Vertex downgraded to Equal Weight from Overweight at Wells Fargo
- Vertex Pharmaceuticals price target lowered to $533 from $535 at Piper Sandler
- Vertex Pharmaceuticals price target lowered to $450 from $456 at Morgan Stanley